NO340089B1 - Fremgangsmåte for å diagnostisere et orofaryngealt plateepitelkarsinom (OSCC) hos et individ ved påvisning av en biomarkør valgt fra gruppen som består av IL8, IL1B, DUSPl, H3F3A, OAZ1, S100P og SAT i cellefritt spytt - Google Patents
Fremgangsmåte for å diagnostisere et orofaryngealt plateepitelkarsinom (OSCC) hos et individ ved påvisning av en biomarkør valgt fra gruppen som består av IL8, IL1B, DUSPl, H3F3A, OAZ1, S100P og SAT i cellefritt spytt Download PDFInfo
- Publication number
- NO340089B1 NO340089B1 NO20064226A NO20064226A NO340089B1 NO 340089 B1 NO340089 B1 NO 340089B1 NO 20064226 A NO20064226 A NO 20064226A NO 20064226 A NO20064226 A NO 20064226A NO 340089 B1 NO340089 B1 NO 340089B1
- Authority
- NO
- Norway
- Prior art keywords
- saliva
- oscc
- mrna
- cancer
- rna
- Prior art date
Links
- 210000003296 saliva Anatomy 0.000 title claims description 182
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 title claims description 142
- 206010031112 Oropharyngeal squamous cell carcinoma Diseases 0.000 title claims description 139
- 208000022698 oropharynx squamous cell carcinoma Diseases 0.000 title claims description 139
- 239000000090 biomarker Substances 0.000 title claims description 128
- 238000000034 method Methods 0.000 title claims description 96
- 102000004890 Interleukin-8 Human genes 0.000 title claims description 72
- 108090001007 Interleukin-8 Proteins 0.000 title claims description 72
- 102100039236 Histone H3.3 Human genes 0.000 title claims description 36
- 102100034428 Dual specificity protein phosphatase 1 Human genes 0.000 title claims description 17
- 101000821881 Homo sapiens Protein S100-P Proteins 0.000 title claims description 17
- 102100021494 Protein S100-P Human genes 0.000 title claims description 17
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 title claims 4
- 101000594698 Homo sapiens Ornithine decarboxylase antizyme 1 Proteins 0.000 title claims 4
- 102100039065 Interleukin-1 beta Human genes 0.000 title claims 4
- 102100036199 Ornithine decarboxylase antizyme 1 Human genes 0.000 title claims 4
- 108091059596 H3F3A Proteins 0.000 title claims 2
- 101000924017 Homo sapiens Dual specificity protein phosphatase 1 Proteins 0.000 title claims 2
- 101000881110 Homo sapiens Dual specificity protein phosphatase 12 Proteins 0.000 title claims 2
- 108091058560 IL8 Proteins 0.000 title claims 2
- 210000001124 body fluid Anatomy 0.000 claims description 53
- 239000010839 body fluid Substances 0.000 claims description 53
- 230000014509 gene expression Effects 0.000 claims description 44
- 238000003753 real-time PCR Methods 0.000 claims description 43
- 238000001514 detection method Methods 0.000 claims description 40
- 238000004458 analytical method Methods 0.000 claims description 35
- 238000010240 RT-PCR analysis Methods 0.000 claims description 29
- 238000010208 microarray analysis Methods 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 description 154
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 124
- 108090000623 proteins and genes Proteins 0.000 description 108
- 210000002966 serum Anatomy 0.000 description 91
- 201000010099 disease Diseases 0.000 description 82
- 206010028980 Neoplasm Diseases 0.000 description 80
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 76
- 201000011510 cancer Diseases 0.000 description 69
- 229940096397 interleukin-8 Drugs 0.000 description 62
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical group C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 62
- 102000004889 Interleukin-6 Human genes 0.000 description 57
- 108090001005 Interleukin-6 Proteins 0.000 description 57
- 229940100601 interleukin-6 Drugs 0.000 description 55
- 239000000523 sample Substances 0.000 description 47
- 230000007170 pathology Effects 0.000 description 43
- 208000035475 disorder Diseases 0.000 description 42
- 239000012071 phase Substances 0.000 description 36
- 230000035945 sensitivity Effects 0.000 description 36
- 101001035966 Homo sapiens Histone H3.3 Proteins 0.000 description 34
- 238000002493 microarray Methods 0.000 description 33
- 239000012530 fluid Substances 0.000 description 30
- 230000000391 smoking effect Effects 0.000 description 28
- 230000003321 amplification Effects 0.000 description 24
- 238000003199 nucleic acid amplification method Methods 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 230000009885 systemic effect Effects 0.000 description 24
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 23
- -1 IL1B Proteins 0.000 description 23
- 239000013615 primer Substances 0.000 description 21
- 238000000692 Student's t-test Methods 0.000 description 20
- 239000007791 liquid phase Substances 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 20
- 238000007477 logistic regression Methods 0.000 description 18
- 239000002299 complementary DNA Substances 0.000 description 17
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 17
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 17
- 108020004635 Complementary DNA Proteins 0.000 description 16
- 102000016544 Ornithine decarboxylase antizyme 1 Human genes 0.000 description 16
- 108050006086 Ornithine decarboxylase antizyme 1 Proteins 0.000 description 16
- 102000004282 Ribosomal protein S9 Human genes 0.000 description 16
- 108090000878 Ribosomal protein S9 Proteins 0.000 description 16
- 238000010804 cDNA synthesis Methods 0.000 description 16
- 108010038537 Dual Specificity Phosphatase 1 Proteins 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 101710115516 Nuclear receptor coactivator 4 Proteins 0.000 description 14
- 102100022927 Nuclear receptor coactivator 4 Human genes 0.000 description 14
- 210000000214 mouth Anatomy 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 238000003491 array Methods 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 238000011529 RT qPCR Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 210000003300 oropharynx Anatomy 0.000 description 9
- 238000010200 validation analysis Methods 0.000 description 9
- 108700039887 Essential Genes Proteins 0.000 description 8
- 238000002123 RNA extraction Methods 0.000 description 8
- 238000013145 classification model Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 7
- 208000003445 Mouth Neoplasms Diseases 0.000 description 7
- 238000002790 cross-validation Methods 0.000 description 7
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 102100034343 Integrase Human genes 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 238000012353 t test Methods 0.000 description 6
- 238000011222 transcriptome analysis Methods 0.000 description 6
- 102100027833 14-3-3 protein sigma Human genes 0.000 description 5
- 108050008974 14-3-3 protein sigma Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000013211 curve analysis Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 231100000283 hepatitis Toxicity 0.000 description 5
- 239000003161 ribonuclease inhibitor Substances 0.000 description 5
- 210000003079 salivary gland Anatomy 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 208000037357 HIV infectious disease Diseases 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
- 230000007813 immunodeficiency Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 108010039627 Aprotinin Proteins 0.000 description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102100022206 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial Human genes 0.000 description 3
- 101710114487 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial Proteins 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100021813 Stress-associated endoplasmic reticulum protein 1 Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 229960004405 aprotinin Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000005251 capillar electrophoresis Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000104 diagnostic biomarker Substances 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000007937 eating Effects 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000004879 molecular function Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 241000945470 Arcturus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 102100020760 Ferritin heavy chain Human genes 0.000 description 2
- 102100031153 Growth arrest and DNA damage-inducible protein GADD45 beta Human genes 0.000 description 2
- 101001002987 Homo sapiens Ferritin heavy chain Proteins 0.000 description 2
- 101001066164 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 beta Proteins 0.000 description 2
- 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 description 2
- 101100043112 Homo sapiens SERPINB3 gene Proteins 0.000 description 2
- 101000616112 Homo sapiens Stress-associated endoplasmic reticulum protein 1 Proteins 0.000 description 2
- 101000838456 Homo sapiens Tubulin alpha-1B chain Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100024923 Protein kinase C beta type Human genes 0.000 description 2
- 102100021258 Regulator of G-protein signaling 2 Human genes 0.000 description 2
- 101710140412 Regulator of G-protein signaling 2 Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 102100036383 Serpin B3 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 102100028969 Tubulin alpha-1B chain Human genes 0.000 description 2
- 238000012197 amplification kit Methods 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000005065 mining Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 208000010655 oral cavity squamous cell carcinoma Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000982889 Homo sapiens Ornithine decarboxylase antizyme 2 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000755529 Homo sapiens Transforming protein RhoA Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 102100027035 Ornithine decarboxylase antizyme 2 Human genes 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101100116844 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) DID2 gene Proteins 0.000 description 1
- 108010029987 Salivary Proteins and Peptides Proteins 0.000 description 1
- 102000001848 Salivary Proteins and Peptides Human genes 0.000 description 1
- 208000026375 Salivary gland disease Diseases 0.000 description 1
- 101100460147 Sarcophaga bullata NEMS gene Proteins 0.000 description 1
- 206010041857 Squamous cell carcinoma of the oral cavity Diseases 0.000 description 1
- 101710084859 Stress-associated endoplasmic reticulum protein 1 Proteins 0.000 description 1
- 102100034998 Thymosin beta-10 Human genes 0.000 description 1
- 102100022387 Transforming protein RhoA Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 208000034940 Undiagnosed disease Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 230000004650 oncogenic pathway Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000010340 saliva test Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000012066 statistical methodology Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 108010044465 thymosin beta(10) Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54650704P | 2004-02-20 | 2004-02-20 | |
| US54652104P | 2004-02-21 | 2004-02-21 | |
| PCT/US2005/005263 WO2005081867A2 (en) | 2004-02-20 | 2005-02-17 | Salivary mrna profiling, biomarkers, and related methods and kits of parts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20064226L NO20064226L (no) | 2006-11-16 |
| NO340089B1 true NO340089B1 (no) | 2017-03-06 |
Family
ID=34915575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20064226A NO340089B1 (no) | 2004-02-20 | 2006-09-19 | Fremgangsmåte for å diagnostisere et orofaryngealt plateepitelkarsinom (OSCC) hos et individ ved påvisning av en biomarkør valgt fra gruppen som består av IL8, IL1B, DUSPl, H3F3A, OAZ1, S100P og SAT i cellefritt spytt |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10072297B2 (enExample) |
| EP (1) | EP1730304B1 (enExample) |
| JP (2) | JP4880484B2 (enExample) |
| KR (2) | KR20070004725A (enExample) |
| CN (1) | CN1977051B (enExample) |
| AU (1) | AU2005216095B2 (enExample) |
| CA (1) | CA2558666C (enExample) |
| IL (1) | IL177579A (enExample) |
| NO (1) | NO340089B1 (enExample) |
| WO (1) | WO2005081867A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005081867A2 (en) * | 2004-02-20 | 2005-09-09 | The Regents Of The University Of C Alifornia | Salivary mrna profiling, biomarkers, and related methods and kits of parts |
| US7727715B2 (en) | 2004-03-30 | 2010-06-01 | Vector Tobacco, Inc. | Global gene expression analysis of human bronchial epithelial cells exposed to cigarette smoke, smoke condensates, or components thereof |
| CA2574706A1 (en) * | 2004-07-21 | 2006-02-23 | The Regents Of The University Of California | Salivary transcriptome diagnostics |
| WO2008001357A2 (en) * | 2006-06-26 | 2008-01-03 | Technion Research & Development Foundation Ltd. | Methods and kits for diagnosing cancer |
| EP2083087B1 (en) * | 2006-10-12 | 2013-05-15 | Niigata University | Method for determining tongue cancer |
| JP2008295327A (ja) * | 2007-05-30 | 2008-12-11 | Fujifilm Corp | 口腔扁平上皮癌の検出方法、及び抑制方法 |
| WO2008157501A1 (en) * | 2007-06-15 | 2008-12-24 | The Regents Of The University Of California | Salivary exon core transcriptome |
| US20090053732A1 (en) | 2007-07-16 | 2009-02-26 | Ophir Vermesh | Microfluidic devices, methods and systems for detecting target molecules |
| WO2010011860A1 (en) * | 2008-07-23 | 2010-01-28 | Diabetomics, Llc | Methods for detecting pre-diabetes and diabetes |
| CA2733246C (en) | 2008-08-04 | 2018-02-20 | Institut Clinident | Method of evaluating oral cancer risk in human |
| US20130143747A1 (en) * | 2011-12-05 | 2013-06-06 | Myriad Genetics, Incorporated | Methods of detecting cancer |
| US9075060B2 (en) | 2009-06-16 | 2015-07-07 | Technion Research & Development Foundation Limited | Methods for diagnosing oral or oral-pharyngeal cancer |
| WO2010151789A1 (en) * | 2009-06-25 | 2010-12-29 | The Regents Of The University Of California | Salivary transcriptomic and microbial biomarkers for pancreatic cancer |
| EP3461912B1 (en) | 2009-09-09 | 2022-07-13 | The General Hospital Corporation | Use of microvesicles in analyzing nucleic acid profiles |
| EP2475989A4 (en) | 2009-09-09 | 2013-02-27 | Gen Hospital Corp | USE OF MICROVESICLES IN THE ANALYSIS OF KRAS MUTATIONS |
| JP2011072229A (ja) * | 2009-09-29 | 2011-04-14 | Keio Gijuku | バイオマーカーとしてのマイクロｒｎａを用いた下咽頭がんの診断・治療選択 |
| US8309299B2 (en) * | 2010-05-19 | 2012-11-13 | Hoffmann-La Roche Inc. | Combination therapy and method for assessing resistance to treatment |
| US20140045915A1 (en) | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| EP2638057B1 (en) | 2010-11-10 | 2019-03-06 | Exosome Diagnostics, Inc. | Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom |
| AU2012314514B2 (en) | 2011-09-26 | 2018-03-15 | Qiagen Gmbh | Stabilisation and isolation of extracellular nucleic acids |
| ES2574956T3 (es) * | 2011-09-26 | 2016-06-23 | Preanalytix Gmbh | Estabilización y aislamiento de ácidos nucleicos extracelulares |
| US11021733B2 (en) | 2011-09-26 | 2021-06-01 | Qiagen Gmbh | Stabilization and isolation of extracellular nucleic acids |
| JP6197039B2 (ja) | 2012-08-24 | 2017-09-13 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ | ハイスループット多重検出用システム、装置及び方法 |
| CA2884915C (en) | 2012-09-25 | 2022-05-17 | Qiagen Gmbh | Stabilisation of biological samples |
| US20140188442A1 (en) * | 2012-12-27 | 2014-07-03 | Pearson Education, Inc. | System and Method for Selecting Predictors for a Student Risk Model |
| WO2014146780A1 (en) | 2013-03-18 | 2014-09-25 | Qiagen Gmbh | Stabilization and isolation of extracellular nucleic acids |
| EP3447141B1 (en) | 2013-03-18 | 2020-08-05 | PreAnalytiX GmbH | Stabilisation of biological samples |
| WO2014182598A1 (en) * | 2013-05-06 | 2014-11-13 | Physicians Choice Laboratory Services, Llc | Diagnostic assay combining cellular and cell free nucleic acid |
| EP3064940B1 (en) * | 2013-10-28 | 2019-07-03 | Salivatech Co., Ltd. | Salivary biomarker for pancreatic cancer |
| US20210005324A1 (en) * | 2018-08-08 | 2021-01-07 | Hc1.Com Inc. | Methods and systems for a health monitoring command center and workforce advisor |
| US12027243B2 (en) | 2017-02-17 | 2024-07-02 | Hc1 Insights, Inc. | System and method for determining healthcare relationships |
| GB201417281D0 (en) * | 2014-09-30 | 2014-11-12 | Ge Healthcare Uk Ltd | Methods and devices relating to the detection of oral cancer biomarkers |
| WO2016090148A1 (en) | 2014-12-03 | 2016-06-09 | IsoPlexis Corporation | Analysis and screening of cell secretion profiles |
| CN114965989A (zh) * | 2015-02-09 | 2022-08-30 | Dna吉诺特克股份有限公司 | 用于采集相关应用、分析和诊断的样本的设备、溶液和方法 |
| US11353448B2 (en) | 2015-02-13 | 2022-06-07 | California Institute Of Technology | Methods and compositions for quantifying metabolites and proteins from single cells |
| DK3262190T3 (da) * | 2015-02-24 | 2021-10-11 | Univ Heidelberg Ruprecht Karls | Biomarkørpanel til påvisning af cancer |
| CA2989199A1 (en) | 2015-07-01 | 2017-01-05 | Duke University | Methods to diagnose and treat acute respiratory infections |
| CN106446599A (zh) * | 2015-08-11 | 2017-02-22 | 中国科学院青岛生物能源与过程研究所 | 一种筛选婴幼儿龋病的口腔致病性生物标记物的方法 |
| CA3005694A1 (en) | 2015-11-20 | 2017-05-26 | Qiagen Gmbh | Method of preparing sterilized compositions for stabilization of extracellular nucleic acids |
| GB201602210D0 (en) | 2016-02-08 | 2016-03-23 | Ucl Business Plc | Detection of cancer |
| WO2018049418A1 (en) | 2016-09-12 | 2018-03-15 | IsoPlexis Corporation | System and methods for multiplexed analysis of cellular and other immunotherapeutics |
| EP4036578A1 (en) | 2016-11-11 | 2022-08-03 | Isoplexis Corporation | Compositions and methods for the simultaneous genomic, transcriptomic and proteomic analysis of single cells |
| CN110226084A (zh) | 2016-11-22 | 2019-09-10 | 伊索普莱克西斯公司 | 用于细胞捕获的系统、装置和方法，以及其制造方法 |
| WO2018217849A1 (en) * | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Targeting of anaplastic lymphoma kinase in squamous cell carcinoma |
| WO2019084351A1 (en) * | 2017-10-27 | 2019-05-02 | The Regents Of The University Of California | SALIVARY EXTRACELLULAR RNA BIOMARKERS FOR GINGIVITIS |
| US20210018507A1 (en) * | 2018-03-04 | 2021-01-21 | Mazumdar Shaw Medical Foundation | Sall.ivary protein biomarkers for the diagnosis and prognosis of head and neck cancers, and precancers |
| EP3671213A1 (en) * | 2018-12-20 | 2020-06-24 | Kromat Muszerforgalmazó Kft. | In vitro method for the diagnosis of malignant conditions |
| WO2020128546A1 (en) * | 2018-12-20 | 2020-06-25 | Kromat Műszerforgalmazó Kft. | A simple, non-invasive method for diagnosing oral cancer |
| JP2020195314A (ja) * | 2019-05-31 | 2020-12-10 | 医薬資源研究所株式会社 | 疾患・体質の分析方法、疾患・体質の分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体 |
| JP7373843B2 (ja) * | 2019-12-19 | 2023-11-06 | 国立大学法人東海国立大学機構 | 感染の原因生物を予測するための予測装置、予測プログラム及び予測方法 |
| CN113985033B (zh) * | 2021-10-19 | 2025-02-14 | 中山大学附属第八医院（深圳福田） | 一种用于诊断骨质疏松症发生肌少症的生物标记物及检测试剂盒 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003009806A2 (en) * | 2001-07-25 | 2003-02-06 | Oncomedx Inc. | Methods for evaluating pathologic conditions using extracellular rna |
| WO2003028531A2 (en) * | 2001-09-28 | 2003-04-10 | Oncomedx, Inc. | Detection of tumor rna in plasma and serum |
| US6607898B1 (en) * | 1996-03-26 | 2003-08-19 | Oncomedx, Inc. | Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6511805B1 (en) | 1996-03-15 | 2003-01-28 | The Penn State Research Foundation | Methods for detecting papillomavirus DNA in blood plasma and serum |
| US20020102553A1 (en) | 1997-10-24 | 2002-08-01 | University Of Rochester | Molecular markers for the diagnosis of alzheimer's disease |
| US6294349B1 (en) * | 1999-03-01 | 2001-09-25 | University Of Mississippi Medical Ctr. | Method of diagnosing and monitoring malignant breast carcinomas |
| US6291663B1 (en) * | 1999-03-03 | 2001-09-18 | Board Of Trustees Of The University Of Arkansas | TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma |
| US6617112B2 (en) | 2000-10-11 | 2003-09-09 | Monsanto Technology Llc | Methods for gene array analysis of nuclear runoff transcripts |
| WO2005081867A2 (en) * | 2004-02-20 | 2005-09-09 | The Regents Of The University Of C Alifornia | Salivary mrna profiling, biomarkers, and related methods and kits of parts |
-
2005
- 2005-02-17 WO PCT/US2005/005263 patent/WO2005081867A2/en not_active Ceased
- 2005-02-17 US US10/589,788 patent/US10072297B2/en active Active
- 2005-02-17 CA CA2558666A patent/CA2558666C/en not_active Expired - Fee Related
- 2005-02-17 AU AU2005216095A patent/AU2005216095B2/en not_active Ceased
- 2005-02-17 EP EP05723309A patent/EP1730304B1/en not_active Expired - Lifetime
- 2005-02-17 JP JP2006554246A patent/JP4880484B2/ja not_active Expired - Fee Related
- 2005-02-17 KR KR1020067018925A patent/KR20070004725A/ko not_active Ceased
- 2005-02-17 CN CN2005800124130A patent/CN1977051B/zh not_active Expired - Fee Related
- 2005-02-17 KR KR1020127034042A patent/KR20130018438A/ko not_active Ceased
-
2006
- 2006-08-20 IL IL177579A patent/IL177579A/en active IP Right Grant
- 2006-09-19 NO NO20064226A patent/NO340089B1/no not_active IP Right Cessation
-
2011
- 2011-05-24 JP JP2011115333A patent/JP5367760B2/ja not_active Expired - Fee Related
-
2014
- 2014-02-18 US US14/182,672 patent/US9983210B2/en active Active
-
2018
- 2018-08-08 US US16/057,911 patent/US20190040471A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6607898B1 (en) * | 1996-03-26 | 2003-08-19 | Oncomedx, Inc. | Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum |
| WO2003009806A2 (en) * | 2001-07-25 | 2003-02-06 | Oncomedx Inc. | Methods for evaluating pathologic conditions using extracellular rna |
| WO2003028531A2 (en) * | 2001-09-28 | 2003-04-10 | Oncomedx, Inc. | Detection of tumor rna in plasma and serum |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011229532A (ja) | 2011-11-17 |
| AU2005216095A1 (en) | 2005-09-09 |
| US20190040471A1 (en) | 2019-02-07 |
| CN1977051A (zh) | 2007-06-06 |
| HK1095163A1 (en) | 2007-04-27 |
| CN1977051B (zh) | 2013-07-17 |
| AU2005216095B2 (en) | 2009-09-17 |
| US9983210B2 (en) | 2018-05-29 |
| EP1730304A2 (en) | 2006-12-13 |
| CA2558666C (en) | 2015-11-24 |
| JP5367760B2 (ja) | 2013-12-11 |
| JP2007522819A (ja) | 2007-08-16 |
| EP1730304B1 (en) | 2013-01-02 |
| JP4880484B2 (ja) | 2012-02-22 |
| WO2005081867A3 (en) | 2006-07-06 |
| WO2005081867A2 (en) | 2005-09-09 |
| US10072297B2 (en) | 2018-09-11 |
| EP1730304A4 (en) | 2007-10-24 |
| CA2558666A1 (en) | 2005-09-09 |
| IL177579A (en) | 2012-03-29 |
| IL177579A0 (en) | 2006-12-10 |
| US20080280772A1 (en) | 2008-11-13 |
| NO20064226L (no) | 2006-11-16 |
| KR20070004725A (ko) | 2007-01-09 |
| US20140249236A1 (en) | 2014-09-04 |
| KR20130018438A (ko) | 2013-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO340089B1 (no) | Fremgangsmåte for å diagnostisere et orofaryngealt plateepitelkarsinom (OSCC) hos et individ ved påvisning av en biomarkør valgt fra gruppen som består av IL8, IL1B, DUSPl, H3F3A, OAZ1, S100P og SAT i cellefritt spytt | |
| Urakami et al. | Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA | |
| Bhargava et al. | HER-2/neu and topoisomerase IIα gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses | |
| CA2904088A1 (en) | Compositions and methods for detecting and determining a prognosis for prostate cancer | |
| AU2012252437A1 (en) | Molecular markers in prostate cancer | |
| AU2005274974B2 (en) | Salivary transcriptome diagnostics | |
| WO2022136472A1 (en) | Biomarkers signature(s) for the prevention and early detection of gastric cancer | |
| Haaland et al. | Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization | |
| CN102154475A (zh) | 一种荧光定量PCR技术检测ERCC1 mRNA表达量的试剂盒 | |
| WO2021030460A1 (en) | Proteogenomic methods for diagnosing cancer | |
| EP3526347B1 (en) | Indoleamine-2,3-dioxygenase assay for prostate cancer diagnosis and prognosis | |
| Khalilianfard et al. | The Role of Salivary Biomarkers in the Diagnosis of Oral Cancer | |
| Yoshii et al. | The expression of SIRT6 is associated with treatment outcome in elder patients with oral cancer | |
| US20090130678A1 (en) | Methods and Kits for Breast Cancer Prognosis | |
| KR102820714B1 (ko) | 신장이식 후 간질 섬유화 및 세뇨관 위축 진단을 위한 정보 제공 방법 | |
| HK1095163B (en) | Methods for salivary mrna profiling | |
| Wullich et al. | Nucleic Acid‐Based Markers in Urologic Malignancies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |